View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
February 20, 2019

Sosei Heptares initiates clinical programme for endocrine disorders

Japan-based biopharmaceutical group Sosei Heptares has initiated clinical development programme of HTL0030310 for the treatment of endocrine disorders, including Cushing's disease.

Japan-based biopharmaceutical group Sosei Heptares has initiated the HTL0030310 clinical development programme for the treatment of endocrine disorders, including Cushing’s disease.

The company has already commenced dosing in a Phase I clinical trial.

HTL0030310 is a small molecule, potent and selective agonist of the somatostatin 5 (SSTR5) receptor. It is developed using the company’s GPCR Structure-Based Drug Design (SBDD) platform.

The compound is designed to regulate the excess release of hormones from pituitary gland adenomas that could lead to a variety of serious endocrine disorders.

It is said to be significantly selective towards SSTR5 and is expected to enhance the balance of efficacy and dose-limiting side effects.

“HTL0030310 is a novel and highly selective molecule, and is the sixth candidate originating from our SBDD platform to advance into human trials.”

The double-blind, randomised, placebo-controlled Phase I trial will evaluate HTL0030310’s safety, tolerability, pharmacokinetics and pharmacodynamics.

It will investigate single ascending subcutaneous doses of the product in a total of up to 64 healthy male and female participants.

With preliminary results anticipated in the second half of this year, the trial data will offer insights into the effect of HTL0030310 on the control of glucose and other endocrine hormones.

Sosei Heptares executive vice-president and chief R&D officer Malcolm Weir said: “HTL0030310 is a novel and highly selective molecule, and is the sixth candidate originating from our SBDD platform to advance into human trials.

“We are not only pleased to begin this new study but also delighted with the productivity of our unique platform to generate attractive candidates targeting GPCRs involved in multiple diseases.

“These candidates present new prospects for our emerging proprietary pipeline, as well as unique opportunities for partnering, and provide a solid foundation to execute our strategy.”

The company’s pipeline comprises multiple product candidates across different therapeutic areas such as immuno-oncology, gastroenterology, inflammation and central nervous system conditions.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena